1. Analyze recent data with CAR T-cell therapies in myeloma, in the context of the current clinical landscape. 2. Implement strategies to monitor and treat adverse events associated with CAR T-cell therapy in the community setting by utilizing effective and coordinated multidisciplinary care teams. 3. Integrate the latest evidence, guidelines, and expert recommendations to make treatment selections, including therapy sequencing and bridging therapies for patients with relapsed/refractory multiple myeloma (RRMM).
- Provider:Medical Education Resources
- Activity Link: https://mycme.com
- Start Date: 2024-10-31 05:00:00
- End Date: 2024-10-31 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 75000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest